Diaceutics Share Price (DXRX)

An alternative sp, target is 144, in the event that my coil interpretation was premature. A reasonable running stop, ought to be maintained, perhaps a multiple of the average true range, below the recent sp, say 2 x ATR or 3 x ATR. DYOR.

The RSI(relative strength index), hidden divergence on 10/5/24, accounted for the subsequent strong rally in sp. Hidden divergence is different from normal divergence, because a lower trough in the RSI, coinciding with a higher trough in the sp, often signals a strong sp, rally.

The sp, chart pattern beginning 2023, shows a large coil price pattern, where resistance and support lines converge. This provides a measured sp, target of 215. Coil price patterns are historically fast moving, when the breakout occurs. Those of a technical interest can use the lower bollinger band turning up , to signal a probable future retracement.

Agree. I think the recent movements are inevitable given the big-name tie-up, but it'll be interesting to see how they're able to capitalise on it to boost sales. I have some doubts but a hold nonetheless

Write up for interest after catching up with the CEO last week.

https://martinflitton1.wixsite.com/privatepunter

Diaceutics PLC - Belfast-based provider of diagnostic commercialisation services to pharmaceutical and biotechnology companies - Announces strategic alliance with KPMG LLC, which provides tax, audit and advisory services and commercialisation solutions for life sciences and healthcare companies. Diaceutics says the partnership will facilitate joint marketing of commercialisation solutions to life science customers for commercialisation of precision medicines.

Diaceutics Chief Executive Officer Ryan Keeling says: "We have worked alongside KPMG leaders for many years with a strong admiration for their work in the precision medicine space. This alliance formally recognises our common goals and ambitions to collectively shape the future of precision medicine...[and] will make it easier for the world's largest and most innovative pharmaceutical and biotech organisations to get access to the best expertise and the best data available."